ASCLEPIUS: Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus

2 December 2024

On 29 November 2024, the kick-off meeting of the project “Advancing scientific collaboration in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus” (ASCLEPIUS), took place in Tbilisi, Georgia.

Coordinated by the G. Eliava Institute of Bacteriophages, Microbiology, and Virology (Eliava), this three-year initiative, funded by Horizon Europe, aims to boost the scientific excellence and innovation capacity of Eliava and its high-quality Twinning partners - l’Institut national de recherche pour l’agriculture, l’alimentation et l’environnement, Universidade do Minho and Intelligentsia Consultants Sarl – to expand their insights in phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus. To achieve this aim, ASCLEPIUS will implement a research and innovation strategy focused upon five objectives:

• Objective 1: Conduct exploratory research on phage therapy for treating Pseudomonas aeruginosa and Staphylococcus aureus.
• Objective 2: Transfer knowledge between experienced researchers of Eliava and the Twinning partners.
• Objective 3: Enhance career prospects of early-stage researchers of Eliava and the Twinning partners.
• Objective 4: Improve Eliava’s management and administrative capacity for European R&D programmes.
• Objective 5: Raise the research profile of Eliava and the Twinning partners.